UPDATE: What happened at the FDA panel review of one Duchenne drug?

Signal by Signal

An FDA panel reviewed a drug for Duchenne muscular dystrophy called drisaperson on Tuesday. What it found is not encouraging. The Signal podcast takes a look at what happened and where things go from here.